EN PL
EDITORIAL ARTICLE
Angiogenesis in rheumatoid arthritis
 
More details
Hide details
 
Online publication date: 2011-03-16
 
 
Reumatologia 2011;49(1):1-9
 
KEYWORDS
ABSTRACT
Angiogenesis is the process of formation of new capillary blood vessels that are generated from pre-existing capillaries. Angiogenesis occurs in postnatal life and is regulated by a complex of proangiogenic and antiangiogenic factors (table I). Upregulated angiogenesis accompanies a few pathological conditions. It is indispensable for growth of malignant tumors. Non-neoplastic diseases are also associated with enhanced angiogenesis, including rheumatoid arthritis. Formation of new vessels was revealed in the inflammed synovial membrane, a key phenomenon of rheumatoid arthritis. Disregulation of pro- and anti-angiogenic factors was shown in rheumatoid patients. Drugs known to inhibit synovitis were found to effect (directly or indirectly) intensity of angiogenesis. It is possible that control of angiogenesis may be one of therapeutical mechanisms of pharmacological management of patients with rheumatoid arthritis.
REFERENCES (26)
1.
Risan W, Flamme I. Vasculogenesis. Ann Rev Cell Dev Biol 1995; 11: 73091.  .
 
2.
Battegay EJ. Angiogenesis: mechanistis insights, neovascular diseases, the therapeutic prospects. J Mol Med 1995; 73: 333-346.  .
 
3.
Gavin TP, Robinsos CB, Yeager RC, et al. Angiogenic growth factor response to acute systemic exercise in human skeletal muscle. J Appl Physiol 2004; 96: 19-24.  .
 
4.
Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.  .
 
5.
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1: 27-31.  .
 
6.
Salke FW, Simsosns M. Angiogenesis in cardiovascular disease. Current status and therapeutic potential. Drugs 1999; 58: 391-396.  .
 
7.
LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996; 22: 675-694.  .
 
8.
Szekenacz Z, Koch A. Angiogenesis and its targeting in rheumatoid arthritis. Vascul Pharmacol. 2009; 51: 1-7.  .
 
9.
Olszewski E, Miodoński AJ. Badania nad unaczynieniem guzów – angiogeneza – zagadnienia nadal aktualne. Terapia 2000; 9: 20-22 .
 
10.
Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003; 2: 127-133. .
 
11.
Małdyk E. Reumatoidalne zapalenie stawów. W: Patomorfologia chorób tkanki łącznej. Małdyk E (red.). PZWL, Warszawa 1981; 144-168. .
 
12.
Szekenacz Z, Koch AE. Vascular involvement in rheumatic diseases: ‘vascular rheumatology’. Arthritis Res Ther 2008; 10: 224-233. .
 
13.
Maruotti N, Cantatore FP, Crivellato E, et al. Angiogenesis in rheumatoid arthritis. Histol Histopathol 2006; 21: 557-566. .
 
14.
Paavonen K, Mandelin J, Partanen T, et al. Vascular endothelial growth factors C and D and their VEGF-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium. J Rheumatol 2002; 29: 39-45. .
 
15.
Ikeda M, Hosoda Y, Hirose S, et al. Expression of vescular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neutrophilin-1 in synovial tissues of rheumatoid arthritis. J Pathol 2000; 191: 426-433. .
 
16.
Giatromalonaki A, Sivridis E, Maltezos E, et al. Upregulated hypoxia inducible factor-1? and 2? pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003; 5: R193-R201. .
 
17.
Paleolog EM, Fava RA. Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies. Springer Semin Immunopathol 1998; 20: 73. .
 
18.
Ballara SC, Taylor PC, Reusch P, et al. Raised serum vescular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001; 44: 2055-2064. .
 
19.
Bodolay E, Koch AE, Kim J, et al. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 2002; 6: 357-376. .
 
20.
Veale DJ, Fearon U. Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. Best Pract Res Clin Rheumatol 2006; 20: 941-947. .
 
21.
Jacq L, Garnier S, Dieudé P. The ITGAV rs3738919-C allele is associated with rheumatoid arthritis in the European Caucasian population: a family-based study. Arthritis Res Ther 2007; 9: R63-R70. .
 
22.
Lainer-Carr D, Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 2007; 3: 434-442. .
 
23.
Kotyla PJ, Śliwińska-Kotyla B, Kucharz EJ. Struktura, metabolizm, funkcja biologiczna i znaczenie kliniczne ensotelin. Post Hig Med Dośw 1993; 43: 345-364. .
 
24.
Kotulska A, Mazurek U, Kotyla U i wsp. Angiostatyna – naturalny inhibitor angiogenezy. Poradnik Farmaceutyczny 2006; 1(22): 1-4. .
 
25.
Kucharz EJ, Kotulska A. Patofizjologiczne rola endostatyny w chorobach nienowotworowych. Pol Arch Med Wewn 2006; 115: 507-511. .
 
26.
Kucharz EJ, Goździk J, Kopeć M, et al. A single infusion of infliximab increases the serum endostatin level in patients with rheumatoid arthritis. Clin Exper Rheumatology 2003; 21: 273-274.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top